GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (NAS:COLL) » Definitions » Market Cap

COLL (Collegium Pharmaceutical) Market Cap : $930.7 Mil (As of Mar. 20, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Collegium Pharmaceutical Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Collegium Pharmaceutical's share price for the quarter that ended in Dec. 2024 was $28.65. Collegium Pharmaceutical's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 31.4 Mil. Therefore, Collegium Pharmaceutical's market cap for the quarter that ended in Dec. 2024 was $900.8 Mil.

Collegium Pharmaceutical's quarterly market cap increased from Jun. 2024 ($1,040.7 Mil) to Sep. 2024 ($1,245.4 Mil) but then declined from Sep. 2024 ($1,245.4 Mil) to Dec. 2024 ($900.8 Mil).

Collegium Pharmaceutical's annual market cap increased from Dec. 2022 ($785.3 Mil) to Dec. 2023 ($980.9 Mil) but then declined from Dec. 2023 ($980.9 Mil) to Dec. 2024 ($900.8 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Collegium Pharmaceutical's Enterprise Value for Today is $1,637.0 Mil.


Collegium Pharmaceutical Market Cap Historical Data

The historical data trend for Collegium Pharmaceutical's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Collegium Pharmaceutical Market Cap Chart

Collegium Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 693.28 628.68 785.30 980.93 900.76

Collegium Pharmaceutical Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 980.93 1,269.65 1,040.70 1,245.37 900.76

Competitive Comparison of Collegium Pharmaceutical's Market Cap

For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Collegium Pharmaceutical's Market Cap Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Market Cap distribution charts can be found below:

* The bar in red indicates where Collegium Pharmaceutical's Market Cap falls into.



Collegium Pharmaceutical Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Collegium Pharmaceutical's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as

Market Cap (A: Dec. 2024 )=Share Price (A: Dec. 2024 )*Shares Outstanding (EOP) (A: Dec. 2024 )
=$28.65*31.440
=$900.8

Collegium Pharmaceutical's Market Cap for the quarter that ended in Dec. 2024 is calculated as

Market Cap (Q: Dec. 2024 )=Share Price (Q: Dec. 2024 )*Shares Outstanding (EOP) (Q: Dec. 2024 )
=$28.65*31.440
=$900.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Collegium Pharmaceutical  (NAS:COLL) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Collegium Pharmaceutical Market Cap Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Collegium Pharmaceutical Business Description

Traded in Other Exchanges
Address
100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Executives
Shirley R. Kuhlmann officer: EVP and General Counsel 780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Thomas B Smith officer: EVP and Chief Medical Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612
Tupper Colleen officer: EVP & Chief Financial Officer C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Scott Dreyer officer: EVP & Chief Commercial Officer 780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Joseph Ciaffoni director, officer: President and CEO 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
John Gordon Freund director 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Rita J. Balice-gordon director C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
John A. Fallon director C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
Gwen A Melincoff director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gino Santini director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Neil F. Mcfarlane director C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Richard Malamut officer: EVP and Chief Medical Officer 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Alison B Fleming officer: Vice President, Product Devlp 780 DEDHAM STREET, SUITE 800, CANTON MA 02021